Mireia Margelí Vila

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial

Evandro de Azambuja, Worta McCaskill‐Stevens, Prudence A. Francis et al. · Breast Cancer Research and Treatment · 2009 · 159 citations · Full text

Big 02-98, Breast Oncology, Oncology +8

Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy As First-Line Treatment for Advanced Breast Cancer: The Letrozole/Fulvestrant and Avastin (LEA) Study

Miguel Martín, Sibylle Loibl, Gϋnter von Minckwitz et al. · Journal of Clinical Oncology · 2015 · 132 citations · Full text

Risk-Adapted Treatment in Clinical Stage I Testicular Seminoma: The Third Spanish Germ Cell Cancer Group Study

Jorge Aparicio, Pablo Maroto, Xavier García del Muro et al. · Journal of Clinical Oncology · 2011 · 127 citations · Full text

A Comprehensive DNA Methylation Profile of Epithelial-to-Mesenchymal Transition

F. Javier Carmona, Verónica Dávalos, Enrique Vidal et al. · Cancer Research · 2014 · 72 citations

Epigenetic Change, Genetics, Dna Methylation +19